Home・Aandelen Lijst・AtriCure Inc

AtriCure Inc

Gesloten

SectorGezondheidszorg

44.15 1.63

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.67

Max

44.41

Belangrijke statistieken
By Trading Economics
Inkomsten	8.8M 9M
Verkoop	12M 154M
K/W Sectorgemiddelde	198.286 57.002
EPS	0.18
Winstmarge	5.83
Werknemers	1,350
EBITDA	-3.8M 3.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+8.74% upside

Dividenden
By Acuity
Volgende Winsten	28 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	357M 2.1B
Vorige openingsprijs	42.52
Vorige sluitingsprijs	44.15

Nieuwssentiment

By Acuity

50%

163 / 340 Rangschikking in Healthcare

AtriCure Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 aug 2026, 20:06 UTC

AtriCure Inc shares are higher today, continuing a nine-session streak of gains. The stock remains above its 20-day moving average.

11 aug 2026, 22:41 UTC

AtriCure Inc shares are higher in after-market trading, continuing a recent trend of strength amid changing monetary policies from central banks.

7 aug 2026, 20:03 UTC

AtriCure Inc's shares are higher during Friday's session, continuing an upward trend since Thursday's close, and remain above their 20-day moving average.

6 aug 2026, 19:12 UTC

AtriCure Inc shares are higher, benefiting from an upward trend in the Health Care Equipment sub-sector. Earlier, the stock peaked before a slight pullback.

5 aug 2026, 19:51 UTC

AtriCure Inc shares are higher today, despite no specific news. Broader market sentiment is cautious following ADP's disappointing employment report.

3 aug 2026, 20:06 UTC

AtriCure Inc. shares are higher during Monday's session, regaining ground after an earlier pullback. Broader market trends support positive investor sentiment.

31 jul 2026, 20:03 UTC

News

AtriCure shares are lower amid significant insider selling, including a $233,280 sale by Chief Scientific Officer Vinayak Doraiswamy and options exercised by Board Member Sven Wehrwein.

30 jul 2026, 18:56 UTC

AtriCure Inc's shares are lower today, impacted by declines in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

29 jul 2026, 20:03 UTC

News

AtriCure Inc shares reached a 52-week high of $43.18 following better-than-expected quarterly earnings, despite a pullback earlier in the session.

28 jul 2026, 19:21 UTC

AtriCure Inc's shares are higher today amid stronger gains in U.S. and European indices, with no specific company news identified for the movement.

27 jul 2026, 20:02 UTC

News

AtriCure Inc shares are higher as the company prepares for two investor conferences and highlights CEO Michael Carrel's leadership appointment.

24 jul 2026, 21:41 UTC

AtriCure Inc. shares traded roughly flat in after-market hours. The stock has performed well recently, positioned near the upper end of its monthly range.

23 jul 2026, 21:51 UTC

News

AtriCure reported strong Q2 results and raised EPS guidance but shares fell in after-market trading, marking the sixth consecutive session of declines.

22 jul 2026, 19:56 UTC

AtriCure Inc shares are trading lower, reaching a session low just before 15:30 ET, despite remaining above the 20-day moving average.

21 jul 2026, 19:16 UTC

AtriCure Inc shares are trading lower today, continuing a trend of declines over the past three sessions, despite gains in the Nasdaq 100 Index.

20 jul 2026, 19:51 UTC

AtriCure Inc continues higher today, maintaining strength since Friday's close, despite a recent pullback earlier in the session.

Peer Vergelijking

Prijswijziging

AtriCure Inc Prognose

Koersdoel

By TipRanks

8.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 47.29 USD 8.74%

Hoogste 55 USD

Laagste 36 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor AtriCure Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan AtriCure Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.